Trial Profile
A Randomised, Double-Blind, Placebo-Controlled Parallel Study to Assess the Safety, Tolerability,Pharmacodynamics and Steady State Pharmacokinetics of Repeated Doses of GW856553 in Patients With COPD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Losmapimod (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors GSK
- 15 Oct 2008 Actual start date changed from Jun 2006 to Aug 2006 as reported by Clinicaltrials.gov
- 10 Sep 2007 New trial record.
- 07 Sep 2007 Status change from recruiting to completed.